Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for PDGFRA D842V-mutant GIST, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No proven therapy after progression on avapritinib.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Cognitive side effects limit dose and quality of life for some patients.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Whether indolent D842V tumours can be watched rather than resected.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Very high, durable response rate in PDGFRA D842V-mutant GIST; approved for that indication in January 2020.
PFS HR 1.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.